The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

avilatx.com

Stage

Acquired | Acquired

Total Raised

$60M

Valuation

$0000 

Revenue

$0000 

About Avila Therapeutics

Avila Therapeutics is developing new medicines that achieve 'protein silencing' based on the proprietary Avilomics platform. Per the company, these medicines, called covalent drugs, strongly and resiliently bond to disease-causing proteins, resulting in therapies that are highly effective against a broad spectrum of human diseases including cancers, autoimmune diseases, and hepatitis C.

Avila Therapeutics Headquarter Location

100 Beaver Street

Waltham, Massachusetts, 02453,

United States

781-891-0086

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Avila Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Avila Therapeutics is included in 1 Expert Collection, including Cancer.

C

Cancer

4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

Avila Therapeutics Patents

Avila Therapeutics has filed 3 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

7/2/2009

10/23/2012

Cyclopropanes, Sulfonamides, Carbamates, Pyrrolidines, Macrocycles

Grant

Application Date

7/2/2009

Grant Date

10/23/2012

Title

Related Topics

Cyclopropanes, Sulfonamides, Carbamates, Pyrrolidines, Macrocycles

Status

Grant

Latest Avila Therapeutics News

Arrakis Therapeutics Appoints Katrine Bosley as Chairman of the Board of Directors

Jan 3, 2020

Arrakis Therapeutics Appoints Katrine Bosley as Chairman of the Board of Directors Entrepreneurial leader brings expertise growing biotech platform companies as former CEO of Editas Medicine and Avila Therapeutics Waltham, Mass., November 21, 2019 — Arrakis Therapeutics , a biopharmaceutical company pioneering the discovery of a new class of small-molecule medicines that directly target RNA, announced today that it has appointed Katrine Bosley as Chairman of its Board of Directors. Ms. Bosley is a proven biotechnology entrepreneur with nearly 30 years of experience in the biotech industry as a leader of emerging companies with broad platforms for innovative medicines. Most recently, Ms. Bosley served as the Chief Executive Officer of Editas Medicine (NASDAQ: EDIT), and previously as CEO of Avila Therapeutics until its acquisition by Celgene Corporation. “Katrine’s experience building dynamic, science-driven companies will serve as a critical resource for Arrakis as we realize our vision of targeting RNA with small molecules to unlock new ways to treat human disease,” said Michael Gilman, Ph.D., CEO of Arrakis. “The breadth of her expertise and her track record of creating value through focused drug development and creative business strategy will be tremendously important to Arrakis as we enter a period of substantial growth in our pipeline and business. I wholeheartedly welcome Katrine to our team and look forward to working together with her to help bring a new class of RNA-targeted medicines to patients.” “Arrakis is leading the creation of RNA-targeted small molecules, an entirely new class of medicines. The company’s platform has the potential to make medicines for hundreds of previously ‘undruggable’ targets,” said Ms. Bosley. “Arrakis is led by a deeply experienced team, many of whom I’ve had the pleasure of working with in the past. It’s rare to have a platform that significantly expands target space while also leveraging all of the benefits of a well-established modality, small molecules. This team knows how to turn this into unprecedented medicines.” Katrine Bosley is an entrepreneur who has built products and companies in the biotech industry for nearly 30 years. She currently serves as a Board member of Galapagos NV (EURONEXT and NASDAQ: GLPG), of Genocea Biosciences (NASDAQ: GNCA) and of the Mass Eye and Ear Institute. Through her career, Ms. Bosley has built and led high-growth companies (Editas Medicine – CEO; Avila Therapeutics – CEO; Adnexus Therapeutics – VP Business Development) and developed innovative products and technologies (CRISPR genome editing, Tysabri (natalizumab), covalent drugs). Her experiences include Chairing the Emerging Companies Section of the Board of BIO; serving as the Entrepreneur-in-Residence at The Broad Institute; and leading a wide range of business transactions (financings, acquisitions, alliances). Ms. Bosley has been recognized as one of the 100 Most Creative People in Business by Fast Company, as CEO of the Year by Xconomy, as one of 30 Global Game Changers by Forbes, as Entrepreneur of the Year by the New England Venture Capital Association, and as one of the Top Ten Women in Biotech by FierceBiotech. About Arrakis Therapeutics Arrakis Therapeutics is a biopharmaceutical company pioneering the discovery of a new class of medicines that directly target RNA. The company has developed a proprietary platform to identify new RNA targets and drug candidates to treat diseases unaddressed by today’s medicines. Arrakis is building a proprietary pipeline of RNA-targeted small molecules (rSMs) focused on cancer and genetically validated targets in other disease areas. The company brings together scientific leaders in RNA structure, chemistry and biology, along with a highly experienced management team and the backing of leading life sciences investors. The company is located in Waltham, Massachusetts. For more information, please visit www.arrakistx.com and engage with us on Twitter @ArrakisTx or on  LinkedIn . # # #

  • Where is Avila Therapeutics's headquarters?

    Avila Therapeutics's headquarters is located at 100 Beaver Street, Waltham.

  • What is Avila Therapeutics's latest funding round?

    Avila Therapeutics's latest funding round is Acquired.

  • How much did Avila Therapeutics raise?

    Avila Therapeutics raised a total of $60M.

  • Who are the investors of Avila Therapeutics?

    Investors of Avila Therapeutics include Celgene, Clovis Oncology, Atlas Venture, Polaris Partners, Abingworth and 4 more.

  • Who are Avila Therapeutics's competitors?

    Competitors of Avila Therapeutics include Armgo Pharma, Sorrento Therapeutics, Epizyme, HumanZyme, Aileron Therapeutics and 13 more.

You May Also Like

Solidus Biosciences Logo
Solidus Biosciences

Solidus Biosciences is a company that received a STTR Phase II grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their award is funded under the American Recovery and Reinvestment Act of 2009 and their project will address further development and commercialization of a multi-enzyme lead optimization chip (Multizyme Chip) for high-throughput generation of lead compound analogs coupled with cell-based screening for the rapid identification of biologically active derivatives. Such a capability directly impacts a key bottleneck in drug discovery; namely, the efficient optimization of lead compounds to develop drugs with optimal pharmacological properties. Solidus Biosciences, Inc. proposes to combine six biocatalysis with pharmacological screening to provide rapid identification of biologically active compounds against cell-specific targets, which is a new paradigm for lead optimization. Moreover, the Multizyme Chip platform will be well-suited for lead optimization in related industries, including agrochemicals, cosmetics, and cosmeceuticals. The Solidus technology will thus improve the competitiveness and efficiency of the pharmaceutical, cosmetics, and chemical industries, and will serve as a rich source of new and improved commercial products. The broader impacts of this research are the advances that Solidus Biosciences will achieve toward generating better and safer drugs, reducing the cost to develop these drugs, and increasing the overall efficiency of the pharmaceutical industry. Solidus will generate Multizyme Chips for purchase by pharmaceutical and biotechnology companies to facilitate their lead optimization programs, particularly those involving natural product-derived and complex synthetic small molecule leads. Cryopreservation techniques developed in Phase II will enable the sale of chips and chip-handling devices produced during Phase I, and will allow seamless penetration of the Solidus technology platform into the company's target markets. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their research project aims to develop a new method for generating lead compounds by using enzymatic modification of compound sets. Availability of new methodology to generate biologically active compounds from existing molecules may enhance the success of the drug discovery process and may lead to the discovery of new and useful therapeutics. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: High-Throughput RNAi Screening of Mammalian Cells. Their research project aims to develop a system for the rapid screening of siRNAs that can inhibit genes involved in cellular responses such as hyperosmotic stress that can affect pathways of high commercial importance, including protein production. Use of hyperosmotic stress as a proof of concept system will demonstrate the feasibility of high-throughput RNAi screening and will at the same time yield results that can be used to improve monoclonal antibody production in commercial and laboratory settings Production of biopharmaceuticals such as antibodies is exquisitely responsive to the culture conditions under which the cells are grown and thus can be improved through optimizing such settings, which in turn, would affect the genes involved in the specific synthetic pathways of interest. Development of a rapid methodology to identify inhibitory RNA molecules that can inhibit genes that adversely affect yield would be of significant importance to pharmaceutical companies that produce protein therapeutics and may result in a lowering of the const of these therapeutic entities.

A
Armgo Pharma

Armgo Pharma is a biopharmaceutical company dedicated to the discovery and development of novel small-molecule therapeutics to treat debilitating cardiac, muscular, and neurological disorders. The company's proprietary drugs, known as rycals, are a new class of oral agents that act on a novel therapeutic target, the ryanodine receptor/calcium release channel (RyR) located on the sarcoplasmic/endoplasmic reticulum of the cell. Rycals act to stabilize these channels and repair the calcium leak caused by stress associated with chronic diseases. It is hypothesized that the leak in the RyR channels, if left untreated, may contribute to disorders affecting the heart, skeletal muscle, and the brain.

S
Sarentis Therapeutics

Sarentis is a start-up biopharmaceutical company focused on the development of therapeutics for the treatment of pain.

N
NeuroGenomeX

NeuroGenomeX is a drug discovery company developing novel treatments for diseases of the brain and nervous system. The current NeuroGenomeX discovery program is focused on therapeutic target areas of epilepsy and traumatic brain injury. NeuroGenomeX is advancing its lead drug candidate, 2-deoxy-D-glucose (2DG), as an anticonvulsant that stops seizures and has beneficial effects against adverse long-term consequences of epilepsy. 2DG also has shown favorable therapeutic neuroprotective effects in animal models of traumatic brain injury (TBI).

T
TheraVida

TheraVida is developing a combination drug product platform, with the potenial to significantly improve existing therapies for a variety of diseases. The company is currently focusing its efforts on the treatment of urological disorders.

NeoClone Logo
NeoClone

NeoClone is a custom monoclonal antibody company focused on developing high quality antibodies for sale as reagents and establishing partnerships and collaborations to develop diagnostic mAbs.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.